73. Who Pays for Multimillion-Dollar Mir...

In the newest show from the Freakonomics Radio Network, host Zachary Crockett explores the hidden side of the things around us. This week: One creature’s trash is another’s cash. (Or, how one man found profit in pee.) Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com ... Show More

A sneak peek at Bapu's new book, Random Acts of Medicine, available now from Doubleday, and an announcement about the show. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising. 

Couples get divorced for all kinds of reasons. Is having kids one of them? Bapu talks about research that investigates what happens to parents who unexpectedly have twins. Plus, an announcement about the future of the show. Hosted by Simplecast, an AdsWizz company. See pcm.adswiz ... Show More

<p>with Andrew Lo (@AndrewWLo) and Jorge Conde (@JorgeCondeBio)</p> <p>The advent of new gene and cell therapies are beginning to approach that holy grail of medicine—that of a possible cure. But they are also more expensive than any medicines ever sold before. In this episode, M ... Show More

Human Genome Editing: The team meet experts at the Human Genome Editing Summit in London, seeking to cure genetic disease and ensure that it's safe and available to all. Roland Pease hears from Victoria Gray, the first person to be cured of the debilitating and life-shortening di ... Show More

It’s widely assumed that drug treatment is a miracle of modern science. However, it’s equally arguable that modern drug treatment is a very expensive disaster, with serious consequences for public health. For example, a drug typically takes 10-12 years to develop and the cost is ... Show More

<p>Original Release on February 6th, 2023: As new gene therapies are researched, developed and begin clinical trials, what hurdles must genetic medicine overcome before these therapies are commonly available? Head of U.S. Pharmaceuticals Terence Flynn and Head of U.S. Biotech Mat ... Show More

If you had a rare disease and the only drug that could help you suddenly shot up in price how would you feel? What if your health service or insurer decided it was too expensive and they wouldn’t fund it any more? This is the problem facing some patients in the Netherlands.In ord ... Show More